On October 29, under the guidance of the Chongqing Women's Federation and jointly sponsored by Aikang Group and the Chongqing Women and Children's Foundation, the 2026 Pink Ribbon Charity Activity "Pink Power to Chongqing" was held in Chongqing. That night, pink ribbons lit up the Chongqing Grand Theater, and the bright pink light bloomed along the river. On the bank of the mighty Yangtze River, the grand and gentle pink power gathered, leaving the care for women in the night.
At the event site, the "2026 Pink Report on Chinese Women's Health" (hereinafter referred to as the "Pink Report") guided by the China Health Economics Research Center of Peking University was officially released. This is also the fifteenth Pink Report launched by Aikang Group. It aims to rely on multi-dimensional data to provide contemporary Chinese women with the latest trends in breast health and continue to convey the health concept of "early prevention, early detection, and early treatment".
When Zhang Ligang, founder and CEO of Aikang Group, released and interpreted the report, he pointed out: "Despite the progress in clinical treatment of breast cancer in recent years, breast cancer is still the leading cause of cancer-related diseases and premature death in women around the world. Early prevention and early screening are the first key line of defense. We hope that through the release of the Pink Report, we will remind women to pay attention to breast screening and take the initiative to pay attention to their own health."
The statistical analysis data of this pink report comes from 2.4685 million adult women (18 years old and above) who participated in physical examinations at the physical examination centers of Aikang Group from July 1, 2025 to June 30, 2026. Among them, 2.3126 million adult women participated in breast-related examinations (including breast surgical examinations, breast imaging examinations, breast cancer-related tumor marker testing and/or breast cancer susceptibility gene testing), and 2.0302 million adult women participated in breast ultrasound examinations.
The pink report shows that among the female physical examination population who underwent breast ultrasound examination, 47.06% were found to have breast nodules. The detection rate has exceeded 2.5 times in 2019. The growth trend cannot be underestimated. Compared with the prediction of 46.71% breast nodule detection rate in 2026 in the "2023 Chinese Women's Health Pink Report", this data has an absolute deviation of less than 0.5%, further verifying the reference value of physical examination big data in predicting disease trends.
Without taking into account variables such as population age structure and national health policies, the Pink Report predicts that by 2029, the breast nodule detection rate among Chinese women may exceed 58%, sounding an alarm for all women.
Observed from the age dimension, the breast nodule detection rate showed a pattern of first increasing and then decreasing, which is basically consistent with the age trend of domestic breast cancer incidence. Among them, women aged 40 to 49, who are in the middle of society, bear the brunt of the disease, with a detection rate of 57.87%, ranking first among all age groups. It is worth mentioning that even young women aged 18 to 29, who are generally considered to be in better health, can hardly escape the attack of breast nodules. The detection rate exceeded the 40% mark for the first time, which is 14.12% higher than the 26.86% in 2022. The trend of rejuvenation is further highlighted.
In terms of geographical divisions, the detection rate of breast nodules continues to follow the pattern over the years. The eastern region is the highest with a value of 48.82%, followed by the central region (43.01%), and the western region is the lowest (39.70%). This distribution trend is also consistent with the geographical distribution of breast cancer incidence rates across the country announced by the National Cancer Center. Looking at Chongqing, which is included in the western sample, the detection rate of breast nodules among local women was 33.30%, which is far lower than the national average. However, behind the relatively eye-catching data, it cannot simply be understood as "sit back and relax". The peak age group for detection of local women is still between the ages of 40 and 49, which is the same as the national risk characteristics. Middle-aged women are still the key group for breast screening.
The pink report shows that Aikang has followed up 633 cases of breast cancer among 2.4685 million adult women undergoing physical examination, of which 95.26% were discovered through breast ultrasound examination. This data also confirms the practical value of breast ultrasound as a primary screening method. According to Aikang follow-up, a total of 94 female breast cancer patients under the age of 40 were found, accounting for 14.8% of all breast cancer patients in this follow-up.
Based on the physiological characteristics of Chinese women, Aikang recommends that: ordinary women should undergo annual screening starting from the age of 35; women over 35 years old and with a family history of breast cancer can shorten the screening to half a year; for BRCA gene mutation carriers, regular screening should be included in the screening starting from the age of 18. On the basis of palpation, it can be combined with targeted examinations such as ultrasound, mammography, breast magnetic resonance MRI, and tumor markers.
In addition to breast cancer, ovarian cancer and cervical cancer have always been two sharp swords hanging over women's reproductive health. As of June 30, 2026, as of June 30, 2026, 34,210 adult women had participated in the Bisiyou-ovarian cancer exosome testing project introduced by Aikang, of which 50 had positive results, with a positive detection rate of 1.46‰. In addition, from March 1, 2023 to October 20, 2026, Aikang Group and Southern Gene conducted HPV testing on 278,070 women who underwent medical examinations. The results showed that 46,972 (16.89%) were infected with HPV, and 11.25% were infected with high-risk HPV.
